Symic Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Symic Biomedical Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C2818
◆発行会社(調査会社):GlobalData
◆発行日:2018年8月
◆ページ数:25
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Symic Biomedical Inc (Symic Biomedical) is a biopharmaceutical company that develops new therapeutics focused on matrix biology. The company’s pipeline products include SB-030 and SB-061. Its SB-030 is a clinical candidate used for the prevention of peripheral vascular diseases or vein graft failure. Symic Biomedical’s SB-061 is a clinical candidate used for disease modification and pain management in the treatment of osteoarthritis. The company also has applications in the areas of fibrosis and oncology. It partners with various pharmaceutical company for the clinical development of osteoarthritis program. Symic Biomedical is headquartered in Emeryville, California, the US.

Symic Biomedical Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Symic Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Symic Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 9
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Symic Biomedical Raises USD30 Million in Series B Venture Financing 11
Symic Biomedical Raises USD25 Million in Series A-2 Financing 12
Symic Biomedical Raises USD15 Million in Series A Financing 13
Symic Biomedical Raises USD0.53 Million in Extended Venture Financing 14
Symic Biomedical Raises US$0.8 Million In Venture Financing 15
Partnerships 16
Symic Biomedical Enters into Co-Development Agreement with Nordic Bioscience 16
Symic Biomedical Inc – Key Competitors 17
Symic Biomedical Inc – Key Employees 18
Symic Biomedical Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Jan 30, 2017: Symic Bio Appoints Scott W. Morrison to Board of Directors 20
Product News 21
05/18/2017: Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee 21
02/24/2017: Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease 22
Clinical Trials 23
Apr 16, 2018: Results from Symic Bio Liver Fibrosis Program Presented at the International Liver Congress 2018 23
Aug 23, 2017: Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis 24
Appendix 25
Methodology 25
About GlobalData 25
Contact Us 25
Disclaimer 25

List of Tables
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Key Facts 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Symic Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Symic Biomedical Inc, Deals By Therapy Area, 2012 to YTD 2018 8
Symic Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 9
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Symic Biomedical Raises USD30 Million in Series B Venture Financing 11
Symic Biomedical Raises USD25 Million in Series A-2 Financing 12
Symic Biomedical Raises USD15 Million in Series A Financing 13
Symic Biomedical Raises USD0.53 Million in Extended Venture Financing 14
Symic Biomedical Raises US$0.8 Million In Venture Financing 15
Symic Biomedical Enters into Co-Development Agreement with Nordic Bioscience 16
Symic Biomedical Inc, Key Competitors 17
Symic Biomedical Inc, Key Employees 18
Symic Biomedical Inc, Other Locations 19

List of Figures
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Symic Biomedical Inc, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[Symic Biomedical Inc:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • miacom diagnostics GmbH-医療機器分野:企業M&A・提携分析
    Summary miacom diagnostics GmbH (miacom) is a molecular diagnostic company that develops and distributes molecular diagnostic tests. The company offers products such as hemoFISH, which identifies sepsis-related pathogens directly from positive blood culture bottles; respiFISH that identifies pathoge …
  • Safaricom Ltd
    Safaricom Ltd - Strategy, SWOT and Corporate Finance Report Summary Safaricom Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Quadra – Power Generation (TGKD):電力:M&Aディール及び事業提携情報
    Summary Quadra - Power Generation (Quadra) is an electric utility. It generates electricity and sells that on wholesale basis and in capacity market; and produces, transports, and sells thermal energy on retail market. The company has production facilities in Lipetsk, Voronezh, Tambov, Kursk, Belgor …
  • Oxford BioTherapeutics Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Oxford BioTherapeutics Ltd (OBT) is a clinical stage oncology company that develops antibody drug conjugates for the treatment of variety of cancers. The company’s product pipelines currently includes T-cell based IO therapies including check point modulators; NK cell based IO therapies such …
  • Gartner, Inc.:企業の戦略・SWOT・財務情報
    Gartner, Inc. - Strategy, SWOT and Corporate Finance Report Summary Gartner, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • SPI Energy Co Ltd:電力:M&Aディール及び事業提携情報
    Summary Spi Energy Co Ltd (Spi Energy), formerly Solar Power Inc, is a photovoltaic (PV) solutions provider. The company offers development, financing, installation, operation and sale of utility-scale and residential solar power projects. It also operates online energy e-commerce and investment pla …
  • Protalix BioTherapeutics Inc (PLX):企業の財務・戦略的SWOT分析
    Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • Bayer AG:企業のM&A・事業提携・投資動向
    Bayer AG - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Bayer AG Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and acquisitions (M&A), divestments, capital …
  • FutureFuel Corp (FF):企業の財務・戦略的SWOT分析
    FutureFuel Corp (FF) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Qdoba Restaurant Corporation:企業の戦略・SWOT・財務情報
    Qdoba Restaurant Corporation - Strategy, SWOT and Corporate Finance Report Summary Qdoba Restaurant Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Feilo Sylvania Europe Ltd:企業の戦略的SWOT分析
    Feilo Sylvania Europe Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products …
  • Telecom Plus plc (TEP):企業の財務・戦略的SWOT分析
    Telecom Plus plc (TEP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • OPG Power Ventures Plc (OPG):企業の財務・戦略的SWOT分析
    OPG Power Ventures Plc (OPG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknes …
  • Synthos SA:企業の戦略的SWOT分析
    Synthos SA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Carondelet Health Network-製薬・医療分野:企業M&A・提携分析
    Summary Carondelet Health Network (Carondelet) is a healthcare service organization that serves through its network of hospitals including St. Mary’s Hospital, St. Joseph’s Hospital and Holy Cross Hospital. The organization provides a wide range of medical and treatment services such as neurology or …
  • Samsung Biologics Co Ltd (207940)-製薬・医療分野:企業M&A・提携分析
    Summary Samsung Biologics Co Ltd (Samsung Biologics) is a biologics development and manufacturing company. The company’s business activities includes process development, contract manufacturing, aseptic fill and finish and project management. Its cell culture development process includes upstream, d …
  • Zaraplast S.A:企業の戦略・SWOT・財務情報
    Zaraplast S.A - Strategy, SWOT and Corporate Finance Report Summary Zaraplast S.A - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • meteocontrol GmbH:電力:M&Aディール及び事業提携情報
    Summary Meteocontrol GmbH (meteocontrol) a subsidiary of S.A.G. Solar GmbH & Co. KG, is a renewable energy company which offers photovoltaic monitoring solutions. The company's product portfolio includes data loggers, WEB'logs, portals, sensor system, grid feed-in management or power control, SCADA …
  • Kimal plc-医療機器分野:企業M&A・提携分析
    Summary Kimal plc (Kimal) is a medical equipment company that develops, manufactures and markets customised procedure packs and vascular access devices. The company’s products include soft tissue biopsy needles, bone marrow biopsy needles, catheter accessories, catheter lock solution, closure device …
  • Ambu AS (AMBU B):企業の財務・戦略的SWOT分析
    Ambu AS (AMBU B) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆